The West Africa @entity2598 ( @entity2598 ) outbreak has reached unprecedented magnitude and caused worldwide concerns for the spread of this deadly virus. Recent findings in nonhuman primates (NHPs) demonstrate that antibodies can be protective against @entity2598 . However, the role of antibody response in vaccine-mediated protection is not fully understood. To address these questions quantitative serology assays are needed for measurement of the antibody response to key Ebola virus (EBOV) proteins. Serology enzyme-linked immunosorbent assays (ELISA's), using a reference detection antibody, were developed in order to standardize the quantitation of antibody levels in vaccinated NHPs or in @entity1 exposed to EBOV or immunized with an EBOV vaccine. Critical reagents were generated to support the development of the serology ELISAs. Recombinant EBOV matrix protein (VP40) was expressed in @entity526 and purified. Two variants of the glycoprotein (GP), the ectodomain lacking the transmembrane domain (GP  TM), and an engineered GP lacking the mucin-like domain (GP  muc) were expressed and purified from @entity1 cell systems. Using these proteins, three ELISA methods were developed and optimized for reproducibility and robustness, including stability testing of critical reagents. The assay was used to determine the antibody response against VP40, GP  TM, and GP  muc in a NHP vaccine study using EBOV virus-like particles (VLP) vaccine expressing GP, VP40 and the nucleoprotein. Additionally, these ELISAs were used to successfully detect antibody responses to VP40, GP  TM and GP  muc in @entity1 sera from EBOV infected individuals.

Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and XXXX .

@entity1 :: ('9606', 'Species') :: ['mammalian', 'humans', 'human'] @entity2598 :: ('MESH:D019142', 'Disease') :: ['Ebola virus disease', 'EVD'] @entity526 :: ('562', 'Species') :: ['Escherichia coli']
@entity1 :: (9606,Species) :: ['humans']
